TRT
TRT delivers large effects on lean mass (Bhasin 1996 dose-response), strength (SMD +0.73 Isidori 2005), libido, and bone density (+7.5% lumbar BMD per T Trials). TRAVERSE 2023 (Lincoff NEJM, n=5,246) confirmed non-inferior MACE versus placebo but flagged AF (HR 1.35), pulmonary embolism (HR 1.92), and AKI (HR 1.55) as new safety signals. Cognition is definitively null per T Trials (Resnick 2017).
TRT scored 6.0 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Pharmaceutical / Drug.
What It Is
Type: Pharmaceutical (androgen replacement; prescription-only; DEA Schedule III).
Current status: Haven't tried.
Testosterone replacement therapy (TRT) restores total and free testosterone to physiological range in men with documented hypogonadism (T <300 ng/dL on two morning draws plus clinical symptoms). Mechanism is direct: exogenous T binds androgen receptors throughout muscle, bone, brain, and adipose, while aromatase converts a portion to estradiol (mandatory for libido, bone health) and 5α-reductase converts another portion to DHT (mediates much of the body-composition and skin/hair effect). HPG axis suppression is the core trade-off: exogenous T shuts down LH and FSH within weeks, leading to testicular atrophy and azoospermia in 90%+ of men by 6 months. Routes range from injectable cypionate (cheapest, most studied) through transdermal gels, pellets, modern oral undecanoate (Jatenzo), and nasal Natesto (uniquely fertility-sparing).
Terminology
- TRT: Testosterone Replacement Therapy.
- HPG axis: Hypothalamic-pituitary-gonadal axis; the GnRH → LH/FSH → testosterone signaling loop.
- TRAVERSE: 2023 RCT of T undecanoate vs placebo in 5,246 hypogonadal men with CV risk; 33-month outcomes.
- T Trials: Coordinated set of 7 NIA-funded RCTs in older hypogonadal men (Snyder 2016 NEJM).
- AR: Androgen Receptor.
- DHT: Dihydrotestosterone, 5α-reductase metabolite of T.
- E2: Estradiol; T aromatizes to E2 via aromatase.
- SHBG: Sex Hormone Binding Globulin; binds T and reduces free T.
- AF: Atrial fibrillation.
- VTE / PE: Venous thromboembolism / pulmonary embolism.
- hCG: Human chorionic gonadotropin; LH-mimetic, preserves spermatogenesis on TRT.
- AI: Aromatase inhibitor (e.g., anastrozole); blocks T → E2 conversion.
- Enclomiphene: SERM that raises endogenous T without HPG suppression; alternative to TRT for secondary hypogonadism.
How this score is calculated →
Upside (3.40 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.8 | 0.950 | |
| Breadth of Benefits | 15% | 4.0 | 0.600 | |
| Evidence Quality | 25% | 3.5 | 0.875 | |
| Speed of Onset | 10% | 3.0 | 0.300 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 3.5 | 0.525 | |
| Total | 3.400 |
Upside Rationale
Efficacy (3.8/5.0) . Large effects in the indicated population. Bhasin 1996 PMID 8637535 dose-response on lean mass (d ~0.7 at physiologic, ~1.5-2.0 at supraphysiologic). Strength SMD +0.73 (Isidori 2005 meta, n=1,083). Body fat SMD -0.77. Bone +7.5% lumbar BMD at 12 months (T Trials Bone substudy). Libido and erectile function modest-to-large in deficient men. HbA1c -0.45% in hypogonadal T2D (TIMES2 PMID 21357472).
Breadth of benefits (4.0/5.0) . Multi-system: muscle, bone, libido, mood, energy, body composition, glycemic control in hypogonadal T2D, anemia correction (Roy 2017 T Trials anemia substudy: 54% vs 15%). Touches nearly every domain of male healthspan.
Evidence quality (3.5/5.0) . T Trials NIA-funded (low industry bias), TRAVERSE 2023 large 33-month CV outcomes, multiple Cochrane reviews. Apply -0.5 industry adjustment for AbbVie funding of TRAVERSE specifically. Cognition arm definitively NULL (Resnick 2017 PMID 28196256) . Caveat against overpromising.
Speed of onset (3.0/5.0) . Sexual function and mood within 3-6 weeks. Body composition 12+ weeks. Bone 12+ months. Hematocrit climbs over 3-6 months. Not a felt-it-today intervention but faster than most longevity protocols.
Durability (1.5/5.0) . Pure functional dependency. Stop TRT and HPG axis takes 3-6 months to resume in secondary hypogonadism, may never resume in primary or in long-term users. Spermatogenesis 6-24 months recovery; 10-20% never recover. Effects of TRT are entirely supplementation-dependent.
Bioindividuality (3.5/5.0) . Strong responders are documented hypogonadal men (T <300, symptomatic), primary hypogonadism (testicular failure), elderly with sarcopenia, men with hypogonadism-driven T2D. Weak or harmed responders include men with reversible lifestyle drivers, those with AF risk, polycythemia history, or planning fertility.
Downside (4.49 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 3.5 | 0.525 | |
| Financial Cost | 5% | 2.5 | 0.125 | |
| Time/Effort Burden | 5% | 2.5 | 0.125 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 4.0 | 0.600 | |
| Reversibility | 25% | 3.5 | 0.875 | |
| Total | 3.575 | |||
| Harm subtotal × 1.4 | 4.480 | |||
| Opportunity subtotal × 1.0 | 0.375 | |||
| Combined downside | 4.855 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 3.515 |
Downside Rationale
Safety risk (4.0/5.0) . CATASTROPHIC RISK FLOOR triggered. Two distinct intrinsic catastrophic pathways: (1) VTE/PE . TRAVERSE PE HR 1.92, statistically significant, intrinsic, dose-dependent; (2) erythrocytosis-mediated stroke via polycythemia (Hct >54% in 5% of TRT users vs 1% placebo). Plus AF HR 1.35, AKI HR 1.55. Floor is a floor, not a stacking ceiling . These signals cluster at 4.0 rather than pushing higher.
Side effect profile (3.5/5.0) . Erythrocytosis (most common dose-limiting AE, route-dependent: IM > pellet > gel > SC > nasal), gynecomastia (high-E2), acne, testicular atrophy, oily skin, mood changes, sleep apnea worsening, edema. Route-specific: IM has injection site soreness; gel has transference risk (FDA black box); oral has BP elevation.
Financial cost (2.5/5.0) . $150-300/mo via TRT telehealth (Defy, Marek, Maximus) including labs. Insurance often covers IM cypionate at <$50/mo at confirmed hypogonadal labs. Affordable for most.
Time/effort burden (2.5/5.0) . Weekly injection (or daily SC, or daily gel application) plus quarterly labs and provider visits. Real ongoing time investment, not trivial.
Opportunity cost (2.5/5.0) . Risks short-circuiting fundamentals. Most men under 50 with low T have correctable lifestyle drivers (sleep, body composition, micronutrients, alcohol, stress). Going on TRT without first fixing those traps men on lifelong replacement. Fertility window closes once HPG axis is suppressed long-term.
Dependency / withdrawal (4.0/5.0) . Functional dependency, not addictive (no reward circuit). HPG axis suppression means stopping crashes T below baseline temporarily; secondary hypogonadism may recover in 3-6 months, primary hypogonadism never recovers. Long-term users (5+ years) may have permanent HPG shutdown. Not addiction-class but strong functional need to continue.
Reversibility (3.5/5.0) . Partially reversible. HPG axis recovery in secondary hypogonadism: 3-6 months. Spermatogenesis: 6-24 months for most, 10-20% never recover. Body composition gains reverse within months of stopping. Some structural changes (BMD gain, jaw widening in younger users) persist but most physiologic effects wash out.
Verdict
✅ Best for: Men 35+ with documented hypogonadism (total T <300 ng/dL on two morning draws plus clinical symptoms) who have ALREADY optimized sleep, body composition, sun exposure, micronutrient status, and stress; men with primary hypogonadism (testicular failure) where lifestyle won't restore levels; well-monitored under endocrinologist or quality TRT clinic with quarterly labs (T, free T, E2-sensitive, hematocrit, PSA, lipids); men with hypogonadism-driven T2D, sarcopenia, or persistent depression after lifestyle work; men using HCG concurrently or enclomiphene alternative if fertility matters.
❌ Avoid if: You have undocumented or low-borderline T at age 25-45 with reversible lifestyle drivers, planned fertility within 12 months without HCG/enclomiphene plan, history of AF or significant CV risk factors (TRAVERSE AF/PE signals), prostate or breast cancer history, untreated severe sleep apnea, polycythemia at baseline (Hct >50%), severe heart failure, or you've been pushed onto TRT by a clinic that didn't run baseline morning labs and lifestyle workup. Also skip if your clinic prescribes anastrozole reflexively without symptomatic high-E2.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ✅ Hormonal / Endocrine Primary | 9.0 | Replacement IS the hormone; direct restoration of total/free T to physiological range. Most direct mechanism in any BioHarmony report. |
| ✅ Libido / Sexual Health Primary | 8.0 | T Trials Sexual Function substudy: large libido improvement (SMD ~0.7) in hypogonadal men. IIEF-EF +2.4 (modest for ED specifically; T is necessary but not sufficient). |
| 💪 Energy / Fatigue Primary | 7.0 | T Trials Vitality substudy: FACIT-F +2.4 vs placebo. Real subjective vitality gain in deficient men. |
| 💪 Body Composition / Fat Loss Primary | 7.0 | Bhasin 1996: dose-response on LBM and fat mass. TRAVERSE +1-1.5 kg LBM, visceral adiposity -11% (CT). SMD -0.77 for body fat (Isidori 2005). |
| 💪 Strength / Power | 7.5 | Isidori 2005 meta SMD +0.73 (n=1,083). Effect proportional to dose; supraphysiological doses extend the curve. |
| 💪 Muscle Growth / Hypertrophy | 7.5 | Direct anabolic via AR signaling and satellite cell activation. Large effect even at physiological replacement. |
| 💪 Bone / Joint Health | 7.0 | T Trials Bone substudy: +7.5% lumbar spine BMD at 12 months. Largest single-year BMD gain of any TRT endpoint. |
| 👍 Mood / Emotional Regulation | 6.5 | Zarrouf 2009 meta: SMD -0.42 for depression. Modest mood lift, not first-line antidepressant. |
| 👍 Recovery / Repair | 6.5 | Anabolic environment improves training recovery; not specifically studied as recovery intervention. |
| 👍 Geriatric / Aging Population | 6.0 | Strong signal in genuinely hypogonadal elderly; AF risk also concentrated in elderly. Net positive in well-selected, cautious in CV-comorbid. |
| 👍 Depression | 6.0 | Zarrouf 2009 meta supports adjunct use in hypogonadal men with comorbid depression. Not for euthymic, eugonadal users. |
| 👍 Metabolic Health | 6.0 | Visceral fat reduction, insulin sensitivity improvement in hypogonadal T2D. |
| ⚖️ Blood Sugar / Glycemic Control | 5.5 | TIMES2 (Jones 2011): HbA1c -0.446% vs +0.147% placebo in hypogonadal T2D men. Real but modest. |
| ⚖️ Healthspan | 5.5 | Body composition + bone + libido + mood improvements support healthspan in deficient men. |
| ⚖️ Injury Recovery | 5.5 | Anabolic environment supports tissue repair; orthopedic injury recovery. |
| ⚖️ Social Bonding / Empathy | 5.5 | Restored libido and confidence support social engagement; hypogonadal men report social withdrawal that improves on TRT. |
| ⚖️ Cardiovascular | 5.0 | TRAVERSE 2023 non-inferior MACE (HR 0.96) BUT new signals: AF HR 1.35, PE HR 1.92, AKI HR 1.55. Net wash with new harm signals. |
| ○ Longevity / Lifespan | 4.5 | All-cause mortality NOT significantly improved in TRAVERSE; hypogonadal men have higher baseline mortality but TRT does not clearly reverse it. |
| ○ Immune Function | 4.5 | T modulates Th1/Th2 balance; clinical immune outcomes in TRT users limited data. |
| ○ Anti-Inflammatory | 4.5 | Modest CRP reduction in hypogonadal men with metabolic syndrome. |
| ○ Endurance / Cardio | 4.5 | Some VO2max improvement in hypogonadal; not a primary endurance intervention. |
| ○ VO2 Max | 4.5 | Same as endurance; modest improvement. |
| ○ Wound Healing | 4.5 | Anabolic state supports wound healing; clinical data thin. |
| ○ Reaction Time / Coordination | 4.5 | Possible improvement via energy/cognition in deficient men; thin specific data. |
| ○ Sleep Quality | 4.0 | Sleep apnea worsening risk (T can increase upper airway collapsibility); some hypogonadal men sleep worse on TRT initially. |
| ○ Anxiety | 4.0 | Mixed; some users report anxiety reduction, others elevation. No strong RCT signal. |
| ○ Stress / Resilience | 4.0 | Indirect via mood and energy improvements. |
| ○ Skin / Beauty | 4.0 | Acne risk in some users (DHT-mediated); generally negative for skin in oily-skin types. |
| ○ HRV / Vagal Tone / Autonomic Balance | 4.0 | Limited direct data. |
| ○ Chronic Pain Management | 4.0 | Hypogonadism associated with chronic pain syndromes; restoration may help. |
| ○ Flow State / Peak Mental Performance | 4.0 | Indirect via energy and motivation; no direct flow research. |
| ○ Mitochondrial | 4.0 | T modulates mitochondrial biogenesis; clinical relevance modest. |
| ○ Traumatic Brain Injury | 4.0 | Hypogonadism common post-TBI; restoration may aid recovery in deficient TBI patients. |
| ○ Memory | 3.5 | T Trials null. No causal effect. |
| ○ Liver / Detoxification | 3.5 | Modern oral undecanoate has BP and HDL signals but no significant hepatotoxicity (unlike methylated forms historically). |
| ○ Neuroplasticity | 3.5 | Mechanistic; no clinical neuroplasticity outcomes. |
| ○ Circadian Rhythm / Chronobiology | 3.5 | T has circadian rhythm; replacement should respect this with morning dosing for some routes. |
| ○ Sleep Architecture (Deep/REM) | 3.5 | No clear architecture benefit; sleep apnea worsening risk. |
| ○ Cognition / Focus | 3.0 | T Trials Cognition substudy (Resnick 2017): definitively NULL. No memory or executive function benefit despite hypogonadal status. |
| ○ Neuroprotection | 3.0 | Mechanistic case but no clinical evidence of neuroprotection. |
| ○ Kidney Function | 3.0 | TRAVERSE flagged AKI HR 1.55. Use caution in CKD. |
| ○ Creativity / Divergent Thinking | 3.0 | No direct evidence. |
| ○ Flexibility / Mobility | 3.0 | No direct effect. |
| ○ Cellular Senescence | 3.0 | Theoretical; no direct evidence. |
| ○ Nerve Regeneration | 3.0 | Animal data; thin human. |
| ○ Respiratory | 3.0 | Sleep apnea risk; otherwise no respiratory effects. |
Frequently Asked Questions
Who actually needs TRT?
Men with documented total T <300 ng/dL on two morning blood draws PLUS clinical symptoms (low libido, ED, fatigue, lean-mass loss, mood) who have ALREADY optimized sleep, body composition, sun exposure, micronutrients (vitamin D, zinc, magnesium), and stress. Per Bhasin 2018 Endocrine Society guidelines. Primary hypogonadism (testicular failure) responds only to T; secondary hypogonadism may respond to enclomiphene first, preserving fertility. Healthy men with low-normal T should fix lifestyle BEFORE TRT.
What did the TRAVERSE trial really show?
TRAVERSE 2023 (Lincoff NEJM, n=5,246, 33 months) confirmed non-inferior MACE (HR 0.96) versus placebo, ending the 2014 Vigen / Finkle CV scare. BUT three new signals emerged: atrial fibrillation HR 1.35 (NNH ~91), pulmonary embolism HR 1.92, acute kidney injury HR 1.55. Plus a counterintuitive fracture signal (HR 1.43). Net: TRT does not increase MI/stroke, but introduces new VTE/AF/AKI risks that didn't exist in the prior null-trial framing. Cardiology now monitors ECG and hematocrit more aggressively in TRT patients.
Will TRT make me infertile?
Yes, almost certainly without intervention. Exogenous T suppresses LH and FSH within weeks, leading to azoospermia in 90%+ of men within 3-6 months. Spermatogenesis recovers in 6-24 months after stopping for most, but 10-20% never fully recover. Mitigation options: add HCG 250-500 IU SC 2-3x/week to maintain testicular signaling, or skip TRT entirely and use enclomiphene 12.5-25 mg/day (a SERM that raises endogenous T without HPG suppression) for secondary hypogonadism. Men planning to conceive within 12 months should not start TRT without explicit fertility planning.
Why does TRT cause atrial fibrillation?
Mechanism is dose-dependent erythrocytosis (T stimulates erythropoiesis, raising hematocrit; >54% triggers therapeutic phlebotomy). Higher viscosity and altered atrial electrophysiology together raise AF risk. TRAVERSE: AF 3.5% vs 2.4% placebo (HR 1.35, NNH 91), PE 0.9% vs 0.5% (HR 1.92), AKI 2.3% vs 1.5% (HR 1.55). Risk concentrates in elderly, polycythemic, and IM-route users (peak/trough swings worse than SC daily). Quarterly hematocrit checks are mandatory; phlebotomy or dose reduction if Hct >54%.
What's the difference between TRT routes (IM vs gel vs pellet vs oral vs nasal)?
IM cypionate weekly is cheapest and most studied but has peak/trough swings driving hematocrit and mood volatility. Daily SC fractionation smooths kinetics. Transdermal gels (AndroGel, Testim) offer steady levels but transference risk requires care around women/children (FDA black box). Pellets (Testopel) Q3-6 months are convenient but non-removable. Modern oral undecanoate (Jatenzo, Tlando) bypasses old liver concerns but has BP elevation and HDL drop. Nasal Natesto (TID dosing) uniquely preserves partial spermatogenesis. Most starts default to IM weekly or SC daily; switch route if AEs.
Should I see my GP or a specialty TRT clinic?
GP/internal medicine often under-monitors and under-treats (single random T draw, no E2/SHBG/free T panel). Endocrinologists are the gold standard but slow to access. Specialty TRT telehealth (Defy Medical, Marek Health, Maximus) generally provides better monitoring including quarterly E2-sensitive, hematocrit, PSA, lipids, with protocol flexibility. Avoid clinics that prescribe without baseline labs, push high-end doses, or routinely add aromatase inhibitors without estradiol confirmation. Always get two morning T draws (8-10 AM, fasted) before starting; T <300 ng/dL on both with symptoms is the floor.
Why do Attia, Huberman, and Galpin all say 'fix fundamentals first'?
Because most low T in men under 50 is downstream of correctable lifestyle: chronic sleep deprivation, excess body fat (aromatizes T to E2), micronutrient deficiency (vitamin D, zinc, magnesium), chronic alcohol, undermuscled body composition, undertraining, chronic stress (cortisol suppresses T). Fixing those routinely raises T 100-300 ng/dL without exogenous hormones, preserves fertility, preserves HPG axis, and avoids dependency. TRT for men in their 30s with reversible lifestyle drivers traps them on lifelong replacement. After fundamentals are optimized for 6-12 months and T remains <300 with symptoms, then TRT becomes appropriate.
What labs do I need before and during TRT?
Baseline: total T (two AM draws), free T, SHBG, estradiol-sensitive (LC/MS), LH, FSH, hematocrit, PSA, lipids, comprehensive metabolic panel. Quarterly first year: trough total T, free T, E2-sensitive, hematocrit (target <54%), PSA (men >40), lipids, ALT/AST. Annually thereafter once stable. Hematocrit >54% requires therapeutic phlebotomy or dose reduction. PSA rise >1.4 ng/mL/yr or >4 absolute warrants urology. E2 < 20 pg/mL associated with joint pain and libido loss; do not crash with anastrozole unless symptomatic high-E2.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension Changes | New Score |
|---|---|---|
| Long-term TRAVERSE follow-up (>5 yr) shows no AF/PE excess after initial signal | Safety 4.0→3.5, Side Effects 3.5→3.0 | 6.6 / 10 👍 Worth trying |
| Independent confirmation of meaningful all-cause mortality benefit in hypogonadal men | Efficacy 3.8→4.3, Evidence 3.5→4.0 | 6.7 / 10 👍 Worth trying |
| Enclomiphene displaces TRT as first-line for secondary hypogonadism (preserves HPG, fertility, no AF signal) | Bioindividuality 3.5→4.0, Reversibility 3.5→2.5 | 6.5 / 10 👍 Worth trying |
| New large-cohort data confirms supraphysiological "biohacker TRT" doubles MACE | Safety 4.0→4.8 (multiple distinct catastrophic signals), Side Effects 3.5→4.0 | 5.4 / 10 ⚖️ Neutral |
| FDA approves Natesto-style fertility-preserving routes as standard, AF/PE signals decline | Safety 4.0→3.0, Reversibility 3.5→2.5 | 6.9 / 10 👍 Worth trying |
Key Evidence Sources
- Lincoff AM et al. (2023) — TRAVERSE: CV outcomes with T-undecanoate, n=5,246. Definitive CV safety RCT; non-inferior MACE but new AF/PE/AKI signals
- Snyder PJ et al. (2016) — Testosterone Trials in older men. NIA-funded T Trials, n=790; sexual, vitality, walking, cognition substudies
- Bhasin S et al. (1996) — Effects of supraphysiologic T doses on muscle. Anchor dose-response on lean mass; classic
- Bhasin S et al. (2018) — Endocrine Society Clinical Practice Guideline. Diagnosis and treatment of hypogonadism; standard of care
- Jones TH et al. (2011) — TIMES2: T undecanoate in T2D hypogonadal men. HbA1c improvement in hypogonadal T2D
- Isidori AM et al. (2005) — Meta-analysis: T effects on body composition and strength. Strength SMD +0.73, body fat SMD -0.77
- Resnick SM et al. (2017) — T Trials Cognition substudy: NULL. Definitive null for cognitive function
- Roy CN et al. (2017) — T Trials Anemia substudy. 54% anemia correction vs 15% placebo
- Vigen R et al. (2013) — Retrospective CV signal that triggered FDA action. Triggered 2014 FDA safety communication; later contradicted by TRAVERSE
- Sharma R et al. (2015) — Veterans cohort: T normalization reduced MI. Counter-signal to Vigen; protective MACE pattern
- FDA Drug Safety Communication (2014) — CV warning for T products. Mandated CV warning; partially walked back post-TRAVERSE
- Zarrouf FA et al. (2009) — T for depression meta-analysis SMD -0.42. Mood/depression effect in hypogonadal men
📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.400 − 4.490 = -1.090
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((-1.090 + 7) / 12) × 10 = 6.0 / 10
